Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.

Helal CJ, Arnold E, Boyden T, Chang C, Chappie TA, Fisher E, Hajos M, Harms JF, Hoffman WE, Humphrey JM, Pandit J, Kang Z, Kleiman RJ, Kormos BL, Lee CW, Lu J, Maklad N, McDowell L, McGinnis D, O'Connor RE, O'Donnell CJ, Ogden A, Piotrowski M, Schmidt CJ, Seymour PA, Ueno H, Vansell N, Verhoest PR, Yang EX.

J Med Chem. 2018 Feb 8;61(3):1001-1018. doi: 10.1021/acs.jmedchem.7b01466. Epub 2018 Jan 16.

PMID:
29293004
2.

Inhibition of Cdk5 Promotes β-Cell Differentiation From Ductal Progenitors.

Liu KC, Leuckx G, Sakano D, Seymour PA, Mattsson CL, Rautio L, Staels W, Verdonck Y, Serup P, Kume S, Heimberg H, Andersson O.

Diabetes. 2018 Jan;67(1):58-70. doi: 10.2337/db16-1587. Epub 2017 Oct 6.

PMID:
28986398
3.

Research Resource: A Dual Proteomic Approach Identifies Regulated Islet Proteins During β-Cell Mass Expansion In Vivo.

Horn S, Kirkegaard JS, Hoelper S, Seymour PA, Rescan C, Nielsen JH, Madsen OD, Jensen JN, Krüger M, Grønborg M, Ahnfelt-Rønne J.

Mol Endocrinol. 2016 Jan;30(1):133-43. doi: 10.1210/me.2015-1208. Epub 2015 Dec 9.

4.

A Gene Regulatory Network Cooperatively Controlled by Pdx1 and Sox9 Governs Lineage Allocation of Foregut Progenitor Cells.

Shih HP, Seymour PA, Patel NA, Xie R, Wang A, Liu PP, Yeo GW, Magnuson MA, Sander M.

Cell Rep. 2015 Oct 13;13(2):326-36. doi: 10.1016/j.celrep.2015.08.082. Epub 2015 Oct 1.

5.

A conserved role for Notch signaling in priming the cellular response to Shh through ciliary localisation of the key Shh transducer Smo.

Stasiulewicz M, Gray SD, Mastromina I, Silva JC, Björklund M, Seymour PA, Booth D, Thompson C, Green RJ, Hall EA, Serup P, Dale JK.

Development. 2015 Jul 1;142(13):2291-303. doi: 10.1242/dev.125237. Epub 2015 May 20.

6.

Altered functional brain network connectivity and glutamate system function in transgenic mice expressing truncated Disrupted-in-Schizophrenia 1.

Dawson N, Kurihara M, Thomson DM, Winchester CL, McVie A, Hedde JR, Randall AD, Shen S, Seymour PA, Hughes ZA, Dunlop J, Brown JT, Brandon NJ, Morris BJ, Pratt JA.

Transl Psychiatry. 2015 May 19;5:e569. doi: 10.1038/tp.2015.60.

7.

The discovery and characterization of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator N-{(3S,4S)-4-[4-(5-cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242).

Shaffer CL, Patel NC, Schwarz J, Scialis RJ, Wei Y, Hou XJ, Xie L, Karki K, Bryce DK, Osgood SM, Hoffmann WE, Lazzaro JT, Chang C, McGinnis DF, Lotarski SM, Liu J, Obach RS, Weber ML, Chen L, Zasadny KR, Seymour PA, Schmidt CJ, Hajós M, Hurst RS, Pandit J, O'Donnell CJ.

J Med Chem. 2015 May 28;58(10):4291-308. doi: 10.1021/acs.jmedchem.5b00300. Epub 2015 May 14.

PMID:
25905800
8.

Pairing-up SOX to kick-start beta cell genesis.

Grapin-Botton A, Seymour PA, Gradwohl G.

Diabetologia. 2015 May;58(5):859-61. doi: 10.1007/s00125-015-3539-2. Epub 2015 Mar 4.

PMID:
25733380
9.

Sox9: a master regulator of the pancreatic program.

Seymour PA.

Rev Diabet Stud. 2014 Spring;11(1):51-83. doi: 10.1900/RDS.2014.11.51. Epub 2014 May 10. Review.

10.

Reduction of brain kynurenic acid improves cognitive function.

Kozak R, Campbell BM, Strick CA, Horner W, Hoffmann WE, Kiss T, Chapin DS, McGinnis D, Abbott AL, Roberts BM, Fonseca K, Guanowsky V, Young DA, Seymour PA, Dounay A, Hajos M, Williams GV, Castner SA.

J Neurosci. 2014 Aug 6;34(32):10592-602. doi: 10.1523/JNEUROSCI.1107-14.2014.

11.

Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating.

Gresack JE, Seymour PA, Schmidt CJ, Risbrough VB.

Psychopharmacology (Berl). 2014 May;231(10):2189-97. doi: 10.1007/s00213-013-3371-7. Epub 2013 Dec 21.

12.

Bulking up on beta cells.

Seymour PA, Serup P.

N Engl J Med. 2013 Aug 22;369(8):777-9. doi: 10.1056/NEJMcibr1307038. No abstract available.

PMID:
23964941
13.

Glenohumeral articular cartilage lesions: prospective comparison of non-contrast magnetic resonance imaging and findings at arthroscopy.

Spencer BA, Dolinskas CA, Seymour PA, Thomas SJ, Abboud JA.

Arthroscopy. 2013 Sep;29(9):1466-70. doi: 10.1016/j.arthro.2013.05.023. Epub 2013 Jul 25.

PMID:
23890951
14.

Pharmacological disruption of mouse social approach behavior: relevance to negative symptoms of schizophrenia.

Hanks AN, Dlugolenski K, Hughes ZA, Seymour PA, Majchrzak MJ.

Behav Brain Res. 2013 Sep 1;252:405-14. doi: 10.1016/j.bbr.2013.06.017. Epub 2013 Jun 25.

PMID:
23806621
15.

A Sox9/Fgf feed-forward loop maintains pancreatic organ identity.

Seymour PA, Shih HP, Patel NA, Freude KK, Xie R, Lim CJ, Sander M.

Development. 2012 Sep;139(18):3363-72. doi: 10.1242/dev.078733. Epub 2012 Aug 8.

16.

A Notch-dependent molecular circuitry initiates pancreatic endocrine and ductal cell differentiation.

Shih HP, Kopp JL, Sandhu M, Dubois CL, Seymour PA, Grapin-Botton A, Sander M.

Development. 2012 Jul;139(14):2488-99. doi: 10.1242/dev.078634. Epub 2012 Jun 6.

17.

Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.

Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, Grimwood S, Guanowsky V, Hajós M, Harms JF, Helal CJ, Hoffmann WE, Kocan GP, Majchrzak MJ, McGinnis D, McLean S, Menniti FS, Nelson F, Roof R, Schmidt AW, Seymour PA, Stephenson DT, Tingley FD, Vanase-Frawley M, Verhoest PR, Schmidt CJ.

J Pharmacol Exp Ther. 2012 May;341(2):396-409. doi: 10.1124/jpet.111.191353. Epub 2012 Feb 10.

18.

Sox9-haploinsufficiency causes glucose intolerance in mice.

Dubois CL, Shih HP, Seymour PA, Patel NA, Behrmann JM, Ngo V, Sander M.

PLoS One. 2011;6(8):e23131. doi: 10.1371/journal.pone.0023131. Epub 2011 Aug 2.

19.

Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain.

Strick CA, Li C, Scott L, Harvey B, Hajós M, Steyn SJ, Piotrowski MA, James LC, Downs JT, Rago B, Becker SL, El-Kattan A, Xu Y, Ganong AH, Tingley FD 3rd, Ramirez AD, Seymour PA, Guanowsky V, Majchrzak MJ, Fox CB, Schmidt CJ, Duplantier AJ.

Neuropharmacology. 2011 Oct-Nov;61(5-6):1001-15. doi: 10.1016/j.neuropharm.2011.06.029. Epub 2011 Jul 7.

PMID:
21763704
20.

α4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties.

Mineur YS, Einstein EB, Seymour PA, Coe JW, O'neill BT, Rollema H, Picciotto MR.

Behav Pharmacol. 2011 Aug;22(4):291-9. doi: 10.1097/FBP.0b013e328347546d.

21.

Historical perspective: beginnings of the beta-cell: current perspectives in beta-cell development.

Seymour PA, Sander M.

Diabetes. 2011 Feb;60(2):364-76. doi: 10.2337/db10-1068. Review. No abstract available.

22.

Sox9+ ductal cells are multipotent progenitors throughout development but do not produce new endocrine cells in the normal or injured adult pancreas.

Kopp JL, Dubois CL, Schaffer AE, Hao E, Shih HP, Seymour PA, Ma J, Sander M.

Development. 2011 Feb;138(4):653-65. doi: 10.1242/dev.056499.

23.

Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists.

Roberts BM, Seymour PA, Schmidt CJ, Williams GV, Castner SA.

Psychopharmacology (Berl). 2010 Jun;210(3):407-18. doi: 10.1007/s00213-010-1840-9. Epub 2010 Apr 20.

PMID:
20401749
24.

Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction.

Roberts BM, Holden DE, Shaffer CL, Seymour PA, Menniti FS, Schmidt CJ, Williams GV, Castner SA.

Behav Brain Res. 2010 Sep 1;212(1):41-8. doi: 10.1016/j.bbr.2010.03.039. Epub 2010 Mar 27.

PMID:
20347881
25.

Glycine transporter inhibition reverses ketamine-induced working memory deficits.

Roberts BM, Shaffer CL, Seymour PA, Schmidt CJ, Williams GV, Castner SA.

Neuroreport. 2010 Mar 31;21(5):390-4. doi: 10.1097/WNR.0b013e3283381a4e.

PMID:
20186106
26.

Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition.

Rollema H, Hajós M, Seymour PA, Kozak R, Majchrzak MJ, Guanowsky V, Horner WE, Chapin DS, Hoffmann WE, Johnson DE, McLean S, Freeman J, Williams KE.

Biochem Pharmacol. 2009 Oct 1;78(7):813-24. doi: 10.1016/j.bcp.2009.05.033. Epub 2009 Jun 6.

PMID:
19501054
27.

Sustained Neurog3 expression in hormone-expressing islet cells is required for endocrine maturation and function.

Wang S, Jensen JN, Seymour PA, Hsu W, Dor Y, Sander M, Magnuson MA, Serup P, Gu G.

Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9715-20. doi: 10.1073/pnas.0904247106. Epub 2009 Jun 1.

28.

Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect.

Rollema H, Guanowsky V, Mineur YS, Shrikhande A, Coe JW, Seymour PA, Picciotto MR.

Eur J Pharmacol. 2009 Mar 1;605(1-3):114-6. doi: 10.1016/j.ejphar.2009.01.002. Epub 2009 Jan 10.

29.

A dosage-dependent requirement for Sox9 in pancreatic endocrine cell formation.

Seymour PA, Freude KK, Dubois CL, Shih HP, Patel NA, Sander M.

Dev Biol. 2008 Nov 1;323(1):19-30. doi: 10.1016/j.ydbio.2008.07.034. Epub 2008 Aug 6.

30.
31.

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.

Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS.

J Pharmacol Exp Ther. 2008 May;325(2):681-90. doi: 10.1124/jpet.107.132910. Epub 2008 Feb 20.

32.

SOX9 is required for maintenance of the pancreatic progenitor cell pool.

Seymour PA, Freude KK, Tran MN, Mayes EE, Jensen J, Kist R, Scherer G, Sander M.

Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1865-70. Epub 2007 Jan 31.

33.

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.

Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, Swick A, Iredale PA.

Neuropharmacology. 2007 Feb;52(2):279-90. Epub 2006 Sep 1.

PMID:
16949622
34.

Pancreatic islet progenitor cells in neurogenin 3-yellow fluorescent protein knock-add-on mice.

Mellitzer G, Martín M, Sidhoum-Jenny M, Orvain C, Barths J, Seymour PA, Sander M, Gradwohl G.

Mol Endocrinol. 2004 Nov;18(11):2765-76. Epub 2004 Aug 5.

PMID:
15297605
35.

Fission of pancreatic islets during postnatal growth of the mouse.

Seymour PA, Bennett WR, Slack JM.

J Anat. 2004 Feb;204(2):103-16.

36.

Dose-specific effects of scopolamine on canine cognition: impairment of visuospatial memory, but not visuospatial discrimination.

Araujo JA, Chan AD, Winka LL, Seymour PA, Milgram NW.

Psychopharmacology (Berl). 2004 Aug;175(1):92-8. Epub 2004 Mar 17.

PMID:
15029470
37.

The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review.

Seymour PA, Schmidt AW, Schulz DW.

CNS Drug Rev. 2003 Spring;9(1):57-96. Review.

38.

Cdk5 as a drug target for the treatment of Alzheimer's disease.

Lau LF, Seymour PA, Sanner MA, Schachter JB.

J Mol Neurosci. 2002 Dec;19(3):267-73. Review.

PMID:
12540052
39.

CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo.

Menniti FS, Buchan AM, Chenard BL, Critchett DJ, Ganong AH, Guanowsky V, Seymour PA, Welch WM.

Stroke. 2003 Jan;34(1):171-6.

40.

Tau protein phosphorylation as a therapeutic target in Alzheimer's disease.

Lau LF, Schachter JB, Seymour PA, Sanner MA.

Curr Top Med Chem. 2002 Apr;2(4):395-415. Review.

PMID:
11966463
41.

Atropisomeric quinazolin-4-one derivatives are potent noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists.

Welch WM, Ewing FE, Huang J, Menniti FS, Pagnozzi MJ, Kelly K, Seymour PA, Guanowsky V, Guhan S, Guinn MR, Critchett D, Lazzaro J, Ganong AH, DeVries KM, Staigers TL, Chenard BL.

Bioorg Med Chem Lett. 2001 Jan 22;11(2):177-81.

PMID:
11206453
42.

Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5.

Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, Nelson RB, McNeish JD.

Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2910-5.

43.

Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist.

Sanner MA, Chappie TA, Dunaiskis AR, Fliri AF, Desai KA, Zorn SH, Jackson ER, Johnson CG, Morrone JM, Seymour PA, Majchrzak MJ, Faraci WS, Collins JL, Duignan DB, Prete Di CC, Lee JS, Trozzi A.

Bioorg Med Chem Lett. 1998 Apr 7;8(7):725-30.

PMID:
9871530
44.

Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor.

McLean S, Ganong A, Seymour PA, Bryce DK, Crawford RT, Morrone J, Reynolds LS, Schmidt AW, Zorn S, Watson J, Fossa A, DePasquale M, Rosen T, Nagahisa A, Tsuchiya M, Heym J.

J Pharmacol Exp Ther. 1996 May;277(2):900-8.

PMID:
8627572
45.

3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.

Howard HR, Lowe JA 3rd, Seeger TF, Seymour PA, Zorn SH, Maloney PR, Ewing FE, Newman ME, Schmidt AW, Furman JS, Robinson GL, Jackson E, Johnson C, Morrone J.

J Med Chem. 1996 Jan 5;39(1):143-8.

PMID:
8568801
46.

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.

Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.

J Pharmacol Exp Ther. 1995 Oct;275(1):101-13.

PMID:
7562537
47.

Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor.

McLean S, Ganong A, Seymour PA, Snider RM, Desai MC, Rosen T, Bryce DK, Longo KP, Reynolds LS, Robinson G, et al.

J Pharmacol Exp Ther. 1993 Oct;267(1):472-9.

PMID:
7693914
48.

Role of prostaglandins in the behavioral changes induced by murine interleukin 1 alpha in the rat.

Otterness IG, Golden HW, Seymour PA, Eskra JD, Daumy GO.

Cytokine. 1991 Jul;3(4):333-8.

PMID:
1873481
49.

1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents.

Lowe JA 3rd, Seeger TF, Nagel AA, Howard HR, Seymour PA, Heym JH, Ewing FE, Newman ME, Schmidt AW, Furman JS, et al.

J Med Chem. 1991 Jun;34(6):1860-6.

PMID:
1676427
50.

4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.

Sarges R, Howard HR, Browne RG, Lebel LA, Seymour PA, Koe BK.

J Med Chem. 1990 Aug;33(8):2240-54.

PMID:
2374150

Supplemental Content

Loading ...
Support Center